

Special Issue

Precision Medicine for Adolescent and Young Adult (AYA) Oncology

Message from the Guest Editor

Adolescents and young adults (AYA, ages 15–39years) affected by cancer have unique treatment, survivorship, and palliation concerns. Precision medicine for adolescent and young adult (AYA) oncology is a rapidly growing field. With a focus on the unique challenges that this age group presents, the issue highlights the importance of precision medicine in improving outcomes and reducing side effects. This Special Issue presents cutting-edge research and clinical advances in precision medicine for AYA oncology. Articles in this issue cover a range of topics, including genomic profiling, targeted therapies, and supportive care for AYA patients. This Special Issue also discusses the use of immunotherapy in AYA oncology, including the challenges and opportunities of using such therapies on this patient population. Original papers are especially encouraged; however, high-level systematic reviews or meta-analyses will also be considered for publication.

Guest Editor

Dr. Amirrtha Srikanthan

1. Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada
2. Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada
3. The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada

Deadline for manuscript submissions

closed (25 December 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/172841

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).